In an era where artificial intelligence (AI) intertwines with medical research, the delineation of truth becomes increasingly complex. This study ostensibly examines a purported novel SARS-CoV-2 variant, dubbed the Omega variant, showcasing 31 unique mutations in the S gene region. However, the real undercurrent of this narrative is a demonstration of the ease with which AI, specifically ChatGPT-4, can fabricate convincing yet entirely fictional scientific data. The so-called Omega variant was identified in a fully vaccinated, previously infected 35-year-old male presenting with severe COVID-19 symptoms. Through a detailed, albeit artificial, genomic analysis and contact tracing, this study mirrors the rigorous methodology of genuine case reports, thereby setting the stage for a compelling but entirely constructed narrative. The entire case study was generated by ChatGPT-4, a large language model by OpenAI. The fabricated Omega variant features an ensemble of mutations, including N501Y and E484K, known for enhancing ACE2 receptor affinity, alongside L452R and P681H, ostensibly indicative of immune evasion. This variant's contrived interaction dynamics - severe symptoms in a vaccinated individual versus mild ones in unvaccinated contacts - were designed to mimic real-world complexities, including suggestions of antibody-dependent enhancement (ADE). While the Omega variant is a product of AI-generated fiction, the implications of this exercise are real and profound. The ease with which AI can generate believable but false scientific information, as illustrated in this case, raises significant concerns about the potential for misinformation in medicine. This study, therefore, serves as a cautionary tale, emphasizing the necessity for critical evaluation of sources, especially in an age where AI tools like ChatGPT are becoming increasingly sophisticated and widespread in their use.

With COVID-19 now pervasive, identification of high-risk individuals is crucial. Using data from a major healthcare provider in Southwestern Pennsylvania, we develop survival models predicting severe COVID-19 progression. In this endeavor, we face a tradeoff between more accurate models relying on many features and less accurate models relying on a few features aligned with clinician intuition. Complicating matters, many EHR features tend to be under-coded, degrading the accuracy of smaller models. In this study, we develop two sets of high-performance risk scores: (i) an unconstrained model built from all available features; and (ii) a pipeline that learns a small set of clinical concepts before training a risk predictor. Learned concepts boost performance over the corresponding features (C-index 0.858 vs. 0.844) and demonstrate improvements over (i) when evaluated out-of-sample (subsequent time periods). Our models outperform previous works (C-index 0.844-0.872 vs. 0.598-0.810).

Why does Covid-19 present itself more severe in some patients but not in others? The question has puzzled researchers and clinicians since the start of the pandemic, but now new research from the EPFL Blue Brain Project may have found a major clue to solving the mystery thanks to machine learning. Analyzing data extracted from 240,000 open access scientific papers, the findings of a paper published in Frontiers revealed the previously undiscovered roles elevated blood glucose levels have in the severity of Covid-19. What makes one person more at risk of developing severe Covid-19 than someone else? While it is widely accepted that elderly people are the most at-risk during the current pandemic, many young, seemingly healthy people have also been hospitalized by the disease.

You are free to share this article under the Attribution 4.0 International license. An advanced machine-learning system can accurately predict if a patient's bout with COVID-19 will become severe or fatal and relay its findings to clinicians. Clinicians often learn how to recognize patterns in COVID-19 cases after they treat many patients with it. Machine-learning systems promise to enhance that ability, recognizing more complex patterns in large numbers of people with COVID-19 and using that insight to predict the course of an individual patient's case. However, physicians sworn to "do no harm" may be reluctant to base treatment and care strategies for their most seriously ill patients on difficult-to-use or hard-to-interpret machine-learning algorithms.